BD, Accelerate to Collaborate on Testing-Kit Distribution
August 15 2022 - 8:12AM
Dow Jones News
By Connor Hart
Becton, Dickinson & Co. and Accelerate Diagnostics Inc. on
Monday said the companies would collaborate to bring rapid
antimicrobial identification and susceptibility to more clinicians
and patients worldwide.
In the collaboration, BD, a Franklin Lakes, N.J.-based medical
technology company, would market and sell Accelerate Diagnostics'
testing kits through its global sales network.
Accelerate, a Tucson, Ariz.-based company, offers rapid testing
solutions for antibiotic resistance and susceptibility, providing
results in hours as opposed to one to two days with some
traditional laboratory methods, the company said.
BD would market and sell two of Accelerate's proprietary testing
kits, one of which is the first test cleared by the U.S. Food and
Drug Administration to deliver both rapid identification and
phenotypic antibiotic susceptibility results in hours direct from
positive blood cultures, the companies said.
"Through our collaboration with Accelerate Diagnostics, we can
help clinicians more quickly, efficiently and effectively treat
patients, which may lead to a reduction in health care costs and
help slow the spread of antimicrobial resistance," said Brooke
Story, president of Integrated Diagnostic Solutions for BD.
Shares of Accelerate rose more than 15% in premarket trading on
Monday, while shares of BD remained steady.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 15, 2022 07:57 ET (11:57 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Apr 2023 to Apr 2024